These findings reflect the challenges in the management of patients with NVAF and a history of ischaemic heart disease and suggest that this subgroup of patients are not treated with evidence-based therapy such as dual antithrombotic therapy (NOACs or VKAs, and P2Y12 inhibitors), or in some cases at least a short course of triple therapy by adding aspirin (e.g., ≤1 week) would be desirable in some AF patients after a recent acute coronary syndrome or undergoing percutaneous coronary intervention [50]. Here, P2RY12 is linked to heart disorder.